Search results for: Adrian Towse
Filter search results
Incentives for R&D for New Antimicrobial Drugs
1 April 2011
…and can be downloaded from: http://www.tandfonline.com/doi/abs/10.1080/13571516.2011.584434 Please cite as: Towse, A. and Sharma, P., 2011. Incentives for R&D for new antimicrobial drugs. International Journal of the Economics of Business, 18(2),…
Using QALYs in Cancer: Review of the Methodological Limitations
1 October 2010
…and can be downloaded from: http://link.springer.com/article/10.2165%2F11588250-000000000-00000 Please cite as: Garau, M., Shah, K.K., Mason, A.R., Wang, Q., Towse, A. and Drummond, M.F., 2011. Using QALYs in cancer. Pharmacoeconomics, 29(8), pp.673-685….
Industrial Policy and the Pharmaceutical Industry
1 January 1995
…dealing with the European Community, Japan and the US are by Yarrow, and Professors Neary and Scherer, respectively. In the fourth paper Hale and Towse assess how valuable the UK-based…
The Future of Primary Care
1 January 1996
…of and solutions to low GP morale, by Professor Mant and Mr Towse. In the final chapter, Professor Roland sets out his vision as to how the dangers of fragmentation…
Improving Efficiency and Resource Allocation in Future Cancer Care
9 January 2016
…M., Welin, K-O., Bianchi, S., Althin, R., O’Neill, P., Persson, U., and Towse, A. (2016) Improving Efficiency and Resource Allocation in Future Cancer Care. OHE Contract Research. Available from https://www.ohe.org/publications/improving-efficiency-and-resource-allocation-future-cancer-care/…
Data Governance Arrangements for Real-World Evidence: South Korea
1 September 2017
…“ideal”, facilitative framework for data governance. 1 Cole, A., Garrison, L., Mestre-Ferrandiz, J., & Towse, A. (2015). Data Governance Arrangements for Real-World Evidence. OHE Consulting Report, London: Office of Health…
Value, Access, and Incentives for Innovation: Policy Perspectives on Alternative Models for Pharmaceutical Rebates
1 March 2019
…Towse, A., Segel C.S., Henshall, C., Pearson, S.D. Value, Access, and Incentives for Innovation: Policy Perspectives on Alternative Models for Pharmaceutical Rebates. Institute for Clinical and Economic Review and the…
Data Governance Arrangements for Real-World Evidence in Japan
1 September 2019
…Hideo Yasunaga and Hayato Yamana through desk research, using the same pre-specified pro-forma as for the previous reports. 1 Cole,A., Garrison,L., Mestre-Ferrandiz,J., Towse,A., 2015. Data Governance Arrangements for Real-World Evidence.OHE…
Cornerstones of “Fair” Drug Coverage: Appropriate Cost – Sharing and Utilization Management Policies for Pharmaceuticals
1 September 2020
…Pearson S, Lowe M, Towse A, Segel C, Henshall C. 2020. Cornerstones of “Fair” Drug Coverage: Appropriate Cost-Sharing and Utilization Management Policies for Pharmaceuticals. Institute for Clinical and Economic Review…